Fremont, California — August 6, 2025 — Leads & Copy — Cytek Biosciences Inc. (Nasdaq: CTKB) announced its second-quarter financial results, reporting total revenue of $45.6 million, a 2% decrease compared to the same period in 2024. The company launched the Cytek Aurora™ Evo system and saw a 16% increase in total recurring revenue. Cytek repurchased $4.5 million of its common stock during the quarter.
CEO Dr. Wenbin Jiang noted steady growth in FSP unit placements and recurring revenue despite a challenging macro environment. The company narrowed its 2025 revenue guidance to a range of $196 million to $205 million.
Second Quarter 2025 Financial Highlights:
Total revenue decreased by 2% to $45.6 million.
Installed base expanded to 3,295 Cytek instruments, a 3% unit growth.
Recurring revenue grew by 16%, comprising 32% of the last 12 months’ total revenue.
GAAP gross profit was $23.9 million, with a 52% margin.
Operating expenses totaled $34.5 million.
Net loss was $5.6 million.
Adjusted EBITDA was $1.3 million.
Cash and marketable securities stood at $262.0 million as of June 30, 2025.
The company will host a conference call on August 6, 2025, to discuss the results.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
Source: Cytek Biosciences, Inc.
